Basel: Novartis has announced the US Food and Drug Administration (USFDA) has approved Cosentyx (secukinumab) for the treatment of active enthesitis-related arthritis (ERA) in four years and older,.
Novartis Cosentyx® receives FDA approval for the treatment of children and adolescents with enthesitis-related arthritis and psoriatic arthritis novartis.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from novartis.com Daily Mail and Mail on Sunday newspapers.
Investegate announcements from NOVARTIS AG CHF0.50(REGD), Novartis Cosentyx® receives FDA approval for the treatment of children and adolescents with enthesitis-related arthritis and psoriatic arthritis